Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors

NCT00415103 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT00415103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00415103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Lead sponsor
PETHEMA Foundation
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2006
Completion date
September 30, 2009
Enrollment
196 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma